The full picture of Merck's 2012 earned, vested, accrued and as-yet-unvested executive compensation levels (in cash, equity, perks and future pension benefits) will be revealed in an as-yet-unfiled SEC proxy statement. However, we just got an "early peek" at part of the haul -- as overnight, SEC Forms 4 were filed by all 14 of the Section 16 reporting executive officers of Merck -- including Chairman and CEO Frazier (his SEC Form 4 is here). Don't misunderstand: they certainly earned it, but it is right, well and good -- that it be widely-disclosed.
Sunshine is the best antiseptic, as ever -- it will prevent any excesses that might otherwise creep into the process, or the outcome (think legacy Schering-Plough, here)
And so, it would seem that the board's compensation committee has determined that the executives have over-acheived the targets laid out in that March 2010 installment of the the Executive Performance Share Units program.
Now we need to wait -- to read the full-narrative, in the proxy -- but here is the footnote to the Forms 4:
. . . .Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/2010. Performance shares were paid out at 107 percent of target awards. . . .
More to come in mid-March, when the Form 10-K and Proxy, proper, are filed.
2 comments:
On a different note, I guess you saw this back on the 22Feb;
http://www.invivoblog.blogspot.com/2013/02/deals-of-week-wonders-what-mercks.html
I'm wondering a bit. Merck bought the S/P group in CA; Dnax (aka Schering Biotech). Why or where is the accountability associated with that group?
Just wondering
Thanks -- I did see that.
Just more of the same -- from those bad old days. Hopefully they have passed, with Mr. Frazier's new leadership at New Merck.
It is maddening, just the same. None of it had to be.
Namaste
Post a Comment